Aisling, Clarus Make Huge Bets On Royalties
This article was originally published in Start Up
When was the last time a life science venture firm spent close to $50 million all in one go? It doesn't happen often, but Aisling Capital and Clarus Ventures have each put up $48.5 million for a tiny slice of sales royalties from ibrutinib, a promising cancer drug that could receive FDA approval this calendar year or early next.
You may also be interested in...
Paying cash up front to scientists, hospitals, biotechs and pharmas in exchange for their royalty stakes in successful drugs has proven profitable for Royalty Pharma. The firm has begun applying its long-term strategy to late-stage clinical candidates in addition to marketed products.
The buyout gives J&J Aragon’s androgen receptor inhibitor similar to Medivation’s Xtandi, a potential blockbuster and competitor. In the process, Aragon’s investors will back new spinout Seragon, created to house an estrogen receptor blocker.
Company Chief Medical Officer Kunkel says FDA has talked about manufacturing and trial design for its breakthrough designee much earlier than would be expected with a typical application.